Philip Velderman, MD
Rheumatology · Holland, MINPI 1366401325
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,638 of the $59,155 with a category attached, or 82.2%. 22 manufacturers reported payments, led by Amgen at 42.2% of the total. Reporting peaked in 2019 at $34,101 and has fallen 99.9% since, to $39 in 2025. Among rheumatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $462.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$25K
- Mallinckrodt Enterprises LLC$18K
- Bristol Myers Squibb$14K
- Mallinckrodt Hospital Products Inc.$2K
- Novartis$125
- Cardinal Health 110 LLC$100
- plus $552 from 16 others
Across 1 payment — averaging $3333.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
What the payments were for
- Consulting fees$5,85310%
- Speaking & faculty fees$48,63882%
- Travel & lodging$2,4724%
- Food & beverage$2,0874%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 43 | $24,968 |
| Mallinckrodt Enterprises LLC | 18 | $17,783 |
| Bristol Myers Squibb | 35 | $13,876 |
| Mallinckrodt Hospital Products Inc. | 3 | $1,751 |
| Novartis | 6 | $125 |
| Cardinal Health 110 LLC | 1 | $100 |
| GSK | 2 | $83 |
| Johnson & Johnson | 2 | $68 |
| Genentech USA, Inc. | 2 | $62 |
| Boehringer Ingelheim | 2 | $48 |
| AbbVie | 3 | $46 |
| Fresenius Kabi USA, LLC | 1 | $33 |
| Radius Health, Inc. | 1 | $31 |
| Pacira Therapeutics, Inc. | 1 | $28 |
| Bioventus LLC | 1 | $25 |
| UCB, Inc. | 1 | $24 |
| AstraZeneca | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Sanofi | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,155 in reported general payments places this provider in the 90th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 53 | $487,937 |
| Humira(Cf) PenAdalimumab | 69 | $468,235 |
| EnbrelEtanercept | 17 | $133,973 |
| Humira(Cf)Adalimumab | 18 | $120,316 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $105,551 |
| Actemra ActpenTocilizumab | 22 | $100,807 |
| Enbrel MiniEtanercept | 12 | $91,579 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $79,481 |
| KevzaraSarilumab | 15 | $64,469 |
| ActemraTocilizumab | 11 | $35,337 |
| Hydroxychloroquine Sulfate | 348 | $24,986 |
| MethotrexateMethotrexate Sodium | 348 | $13,686 |
| Prednisone | 399 | $3,448 |
| Leflunomide | 36 | $3,366 |
| Celecoxib | 62 | $3,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $24,968 | $133,97317 claims |
| AbbVieHumira(Cf) | $46 | $120,31618 claims |
| UCB, Inc.Cimzia (2 Pack) | $24 | $79,48112 claims |
| SanofiKevzara | $14 | $64,46915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Holland
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
- Roman CzubatyjRochester Hills$764K
- Delfin SantosRochester$242K
- Allan MortonWarren$229K
- Elena SchiopuAnn Arbor$180K
- Alireza MeysamiNovi$170K
- Fazleomar MahmoodChelsea$167K
- Barakat ThabetGrand Rapids$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.